Navigation Links
Oncos Therapeutics raises €4 million ($5.3 million) to develop oncolytic viruses into cancer treatment
Date:4/28/2010

Oncos Therapeutics, a biotech company developing new cancer therapeutics based on its next generation oncolytic viruses, completed a 4 million ($ 5.5 million) investment from HealthCap. With committed capital exceeding 800 million, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe.

After treating 200 late stage cancer patients since 2007 with strong safety and efficacy results, Oncos has selected its modified oncolytic adenovirus CGTG-102 as its lead clinical candidate. "This is the first step to turn our Advanced Therapy Access Program results into cancer therapeutics", says Pekka Simula, CEO and co-founder.

"The results have been strong for late stage solid tumor cancers where routine therapies have failed.Time is critical in the treatment of cancer. We are confident that when treating earlier stage patients, our oncolytic virus therapy will prove even more significant", says Research Professor Akseli Hemminki, CSO and co-founder, and a research group leader at the University of Helsinki.

"Oncolytic viruses are maturing as a new treatment modality in cancer. Oncos, as one of the leading companies in the field, combines very promising results in humans with strong science", comments Dr Johan Christenson, partner with HealthCap.


'/>"/>

Contact: Timo Ahopelto
timo.ahopelto@oncos.com
358-400-569-628
University of Helsinki
Source:Eurekalert

Page: 1

Related medicine news :

1. Cambridge Healthtech Announces Its Inaugural Encouraging Development of Therapeutics for Neglected Diseases Conference
2. Study says therapeutics for trauma patients may not be effective due to an infection
3. United Therapeutics Corporation Withdraws European Marketing Authorization Application for Tyvaso for the Treatment of Pulmonary Arterial Hypertension
4. Northwest Biotherapeutics Inc. Appoints Market Media Connect as Communications Agency of Record
5. Echo Therapeutics Provides Business Update
6. Reportlinker Adds The Future of Respiratory Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
7. Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
8. Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
9. Anesiva Stockholders Approved Merger With Arcion Therapeutics but Merger Remains Contingent on Other Closing Conditions
10. Osseon Therapeutics, Inc. Announces it has Received Canadian Medical Device Licenses From Health Canada
11. Development of Newer Therapies to Treat Lifestyle Disorders and Reduce the Risk of Co-morbidities is Key to the Expansion of the European Lifestyle Disorders Therapeutics Market, Says Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... ... services for life science companies, has achieved ISO 17100:2015 certification following a ... ISO 17100 is the globally recognized standard that establishes guidance for critical ...
(Date:1/23/2017)... ... 2017 , ... The iaedp Foundation, recognized for its excellence ... treat the full spectrum of eating disorder problems, proudly announces the addition of ... the leading eating disorder treatments centers located throughout the U.S. As partners of ...
(Date:1/23/2017)... ... January 23, 2017 , ... Sharon Kleyne, America’s leading water researcher, advocate ... about the benefits of making new water infrastructure a number one priority. “As we ... we expect water infrastructure to become a top priority of our new political change ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... Crystallization in Process Chemistry by Applying Simple PAT Tools . , Crystallization ... isolate and purify the desired product. Chemists now spend more time developing ...
(Date:1/23/2017)... ... ... is a set of camera tools that allow video editors to integrate up to two ... Christina Austin - CEO of Pixel Film Studios. , With ProRandom, video editors can ... ProRandom works by using a virtual camera to create the illusion of a shaky camera. ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... -- Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... Report Highlights: The report ... the investment opportunities Market forecasts till 2025, using estimated ... across the business segments, Regions and Countries Key developments ...
(Date:1/23/2017)... , Jan. 23, 2017  Using Astute ... at high risk for acute kidney injury (AKI) ... by globally-recognized care guidelines significantly improved ... severe AKI more than 33 percent, according to ... the journal Intensive Care Medicine. ...
(Date:1/23/2017)... 23, 2017 Ahead of today,s trading session, ... they have fared at the close: Kite Pharma Inc. (NASDAQ: ... OVAS ), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ... relative laggards on Friday, January 20 th , 2017, down on ... reports on these stocks now at: ...
Breaking Medicine Technology: